



NERVGEN PRESENTING STUDY DESIGN FOR UPCOMING PHASE 1B/2A IN ALZHEIMER'S DISEASE AT THE 2022 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Vancouver, Canada August 2, 2022 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster summarizing unblinded data from the single ascending dose (SAD) cohort of the study and interim blinded data from the multiple ascending dose (MAD) portion of the study, and for the first time will introduce the study design for the upcoming Phase 1b/2a trial of NervGen's lead drug candidate, NVG-291, in subjects with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Dr. Mikol stated, "I am very excited about sharing our trial design at AAIC. Importantly, it was developed with substantial input from our distinguished [Alzheimer's Disease Clinical Advisory Board](#) which is comprised of leading physicians and researchers in Alzheimer's disease."

[George Perry, PhD](#), Founding Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio, and member of NervGen's Alzheimer's Disease Clinical Advisory Board, stated, "I believe NVG-291's novel mechanism of action and the demonstration of function improvement in several different animal models of nervous system damage is of significant interest to the Alzheimer's disease field. I'm excited about playing a part in testing this drug in patients so we can determine if the repair mechanisms such as increased plasticity, axonal regeneration and remyelination results in favorable effects in Alzheimer's disease patients."

Paul Brennan, NervGen's President & CEO, stated, "NVG-291 has significant potential to repair the damage from this relentlessly progressive disease. Given the unique mechanism of NVG-291, we believe we have an opportunity to see changes in imaging biomarkers in this trial, which has been designed to give us the best opportunity to detect efficacy in Alzheimer's patients."

About Alzheimer's Association International Conference

The Alzheimer's Association International Conference (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer's disease.

About NervGen

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen's lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company's initial target indications are Alzheimer's disease, spinal cord injury and multiple sclerosis. For more information, go to www.nervgen.com.



About NVG-291

NervGen holds the exclusive worldwide rights to NVG-291 and is developing a unique new class of drugs around the technology. NVG-291 is a therapeutic peptide that mimics the intracellular domain of the receptor protein tyrosine phosphatase sigma (PTP σ), a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs). Both PTP σ and CSPGs have been shown to inhibit neural repair mechanisms following nervous system damage. NVG-291-R, the rodent form of NVG-291, has been shown to promote functional recovery and enable nervous system repair in a range of animal models, including models of spinal cord injury, peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination.

For further information, please contact:

Huitt Tracey, Corporate Communications

htracey@nervgen.com

604.362.6209

Nancy Thompson, Vorticom Public Relations

nancyt@vorticom.com

212.532.2208

Follow NervGen on [Twitter](#), [LinkedIn](#), and [Facebook](#) for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: our plans to present unblinded data from the SAD cohort of the study and interim blinded data from the MAD portion of our Phase 1 study; the timing, objectives and study design of the clinical development of NVG-291, including the planned Phase 1b/2a clinical trial in Alzheimer’s disease and the ongoing Phase 1 study in healthy volunteers; our belief that NVG-291’s novel mechanism of action and the demonstration of function improvement in several different animal models of nervous system damage is of significant interest to the Alzheimer’s disease field; NVG-291’s significant potential to repair the damage from Alzheimer’s disease; the opportunity to see changes in imaging biomarkers in this trial which has been designed to give us the best opportunity to detect efficacy in Alzheimer’s disease patients; that we are developing a unique new class of drugs around the technology of NVG-291; the timing and requirements to remove the partial clinical hold initiated by the FDA; the clinical development of NVG-291 for Alzheimer’s disease, multiple sclerosis and spinal cord injury; the belief that inhibiting the activity of PTP σ is a promising target for reducing the



clinical effects of nervous system damage through multiple mechanisms; and the development of innovative treatments that enable the nervous system to repair itself following damage.

Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company's ability to manage the effects of the COVID-19 pandemic; the accuracy of the Company's financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.

Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of the COVID-19 pandemic, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's Annual Information Form, Prospectus Supplement, financial statements and Management Discussion and Analysis which can be found on SEDAR.com. All clinical development plans are subject to additional funding.

Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.